FDA Clears AI-Based Type 2 Diabetes Clinical Decision Support System

In October, DreaMed Diabetes AI LTD. announced that it received its fourth U.S. Food and Drug Administration (FDA) clearance for its Advisor Pro AI Clinical Decision Support System, which expands the platform’s target population to patients with both type 1 and type 2 diabetes.

Advisor Pro is a decision support system cleared to assist healthcare providers in the management of diabetes patients who use insulin pumps or injections and monitor their glucose using continuous glucose monitor and/or blood glucose meters.

The system leverages the power of artificial intelligence to optimize insulin administration. Advisor Pro aims to empower primary care clinicians, such as PCPs and NPs, to provide expert level endocrinological care to diabetes patients.

DreaMed Advisor Pro previously received a CE Mark and was cleared by the FDA for people with type 1 diabetes using insulin pump therapy with continuous glucose sensors and/or blood glucose meters and is already deployed by leading diabetes treatment centers, including Yale New Haven Health, Texas Children’s Hospital, the University of Florida, and more.

“Chronic diseases require constant care by experts,” says Moshe Phillip, MD, DreaMed’s chief science officer and the director of the Endocrinology and Diabetes Institute at Schneider Children’s Medical Center in Israel. “DreaMed has done significant clinical research to achieve a strong AI-based clinical decision support system that has just received the necessary FDA clearance. DreaMed Advisor Pro greatly expands the access to the much-needed expert-level care to millions of people. We are proud of this achievement and committed to work hard on its expansion to additional capabilities and treatment methods.”

You may also like

  • Study Links Diabetes and Worse Outcomes in Long-Term Survivors of Metastatic Breast Cancer

    Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a study presented at ENDO 2022. The authors of the study point out that a well-established relationship between diabetes and breast cancer exists, but it’s still unclear how…

  • Islets in the Stream: Could Stem Cell Technology Be an Eventual Cure for Type 1 Diabetes?

    Recent studies have shown how stem cell-derived therapies have the potential as a renewable source of insulin-producing pancreatic islet cells. Promising as these results are, could stem cell technology eventually lead to a cure for diabetes as well as impacts well beyond endocrinology? Last December, two papers appeared in Cell Stem Cell and Cell Reports…